GLP-1 and Cardiovascular Health: What Science Has Already Shown

For decades, medications in the GLP-1 agonist class were associated almost exclusively with blood sugar control and weight loss. The narrative began to change significantly when the results of a large clinical study started circulating through the medical community. This is the SELECT trial, a research conducted with more than 17,000 participants around the world, and its findings shook the field of cardiology.

What the SELECT Trial Showed

The study investigated people with established cardiovascular disease and obesity, but without a diagnosis of diabetes. Participants who received semaglutide once a week showed a 20% reduction in the risk of major cardiovascular events, such as heart attack, stroke, and cardiovascular death. These numbers represent more than a statistical reduction. In practice, they mean that out of every 100 people treated over approximately three years, at least a few would avoid an event that could change or shorten their lives.

This result was considered a turning point. Until then, no weight loss medication had demonstrated so clearly a direct impact on heart protection. Semaglutide showed that weight loss alone was not the only factor at play. The medication acts on biological pathways that influence vascular inflammation, endothelial function, and lipid metabolism.

Why the Heart Benefits Before Complete Weight Loss

One observation that caught researchers' attention was that cardiovascular protection began to appear relatively early in treatment, often before participants lost significant amounts of weight. This suggests that GLP-1 acts on mechanisms that go beyond aesthetics or the number on the scale.

Chronic low-grade inflammation is recognized today as one of the pillars of atherosclerosis development. Substances released by excess adipose tissue keep the immune system in a permanent state of alert, damaging artery walls over years. Semaglutide reduces inflammatory markers consistently, and this anti-inflammatory action may explain part of the cardiovascular benefit that goes beyond weight loss.

Additionally, GLP-1 improves the lipid profile of many patients. This is not a dramatic change in cholesterol numbers, but a modest, steady effect that, combined with other actions of the molecule, contributes to a more welcoming vascular environment for arteries.

The Role of Blood Pressure and Heart Rate Control

Hypertension is one of the most prevalent risk factors among people with obesity and cardiovascular disease. GLP-1 agonists frequently promote modest reductions in systolic blood pressure, in the range of 2 to 6 mmHg on average. It seems small, but any health professional knows that even small sustained reductions in blood pressure represent tangible reductions in the risk of future events.

Resting heart rate also tends to decrease slightly with continuous use of these medications. A lower, more stable heart rate means less stress on the heart muscle over time. For someone who has already had a heart attack, for example, this relief in cardiac demand represents an important difference in quality of life and prevention of new events.

What This Means for People Living With Obesity and Cardiovascular Risk

Receiving a cardiovascular disease diagnosis or knowing that you are at high risk naturally generates a lot of anxiety. The feeling that the body betrayed you is common, and the list of care requirements can seem infinite. Medications, diet, exercise, sleep, stress control. The good news that the SELECT trial brought is that there is now a therapeutic tool that acts on several of these fronts at the same time.

For those seeking support in this process, there are apps developed to help monitor GLP-1 treatment, with dose logging, effect tracking, and practical tips for each phase. An example is Ozempro, which offers an initial quiz for those who want to understand better how treatment can fit into their routine. You can start here: https://www.ozempro.com/quiz.

Regular follow-up with the doctor is irreplaceable, of course. But having a tool that helps maintain treatment rhythm, reminds you of doses, and allows you to record how the body is responding makes a difference in the daily life of many people. GLP-1 is not a magic solution, but it is proving to be a considerably strong ally for those dealing with the cardiovascular complications of obesity. The Ozempro app, for example, allows this follow-up to be done simply and organized.

Where Science Intends to Go

The SELECT trial data opened the path for semaglutide to receive regulatory approvals in new countries specifically for a cardiovascular indication. This changes the way doctors around the world prescribe the medication. The next step is to better understand which groups benefit most, which treatment combinations work best, and how to integrate the use of these medications with lifestyle changes sustainably.

The field is moving fast. Every month, new data reinforces the role of GLP-1 agonists beyond blood sugar control. For patients and health professionals, it means more options and more hope. For those who follow the evidence closely, it is clear that we are facing a genuine change in the treatment of cardiometabolic diseases.

The most important thing is always to talk with your doctor about the available options and check whether GLP-1 is an appropriate alternative for your case. Ozempro can be an interesting starting point for those who want to better organize this journey and understand better how each stage of treatment with GLP-1 agonists works.

References

• EMA — Ozempic (semaglutida), EPAR
• Wilding et al., STEP 1 — NEJM (2021)
• Lincoff et al., SELECT — NEJM (2023)